Respiratory syncytial virus-immunogloblulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: Part II

Journal of Pediatric Health Care

Volumn 12, Issue 2, 1998, Pages 85-89

  Sandritter, Tracy L ^a   Kraus, Donna M ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b M/C 886 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS;

CHILD; DRUG MONITORING; ECONOMICS; HUMAN; PEDIATRIC NURSING; REVIEW; VIRUS INFECTION;

CHILD; DRUG MONITORING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PEDIATRIC NURSING; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 0032018815     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0891-5245(98)90227-9     Document Type: Article

References (18)

1. American Academy of Pediatrics: Committee on Infectious Diseases, Committee on Fetus and Newborn. (1997). Respiratory syncytial virus immune globulin intravenous: Indications for use. Pediatrics, 99, 645-650.
2. Grier, C.E., & Howe, B.J. (1995, October). Economic impact of pneumonia due to respiratory syncytial virus (RSV) infection [abstract]. Presented at the Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
3. Groothuis, J.R., Simoes, E.A.F., Levin, M.J., Hall, C.B., Long, C.E., Rodriguez, W.J., Arrobio, J., Meissner, H.C., Fulton, D.R., Welliver, R.C., Tristram, D.A., Siber, G.R., Prince, G.A., Van Raden, M., Hemming, V.G., & the RSVIG study group. (1993). Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The New England Journal of Medicine, 329, 1524-1530.
4. Hay, J.W., Ernst, R.L., & Meissner, C. (1996). Respiratory syncytial virus immune globulin: A cost-effectiveness analysis. The American Journal of Managed Care, 2, 851-861.
5. Meissner, H.C., Welliver, R.C., Chartrand, S.A., Fulton, D.R., Rodriguez, W.J.A., & Groothuis, J.R. (1996). Prevention of respiratory syncytial virus infection in high risk infants: Consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. The Pediatric Infectious Disease Journal, 15, 1059-1068.
6. O'Shea, T.M., Sevick, M.A., & Givner, L.B. (1997). Cost and benefits of prophylaxis of very low birth weight (VLBW) infants with respiratory syncytial virus (RSV) immune globulin [abstract]. Pediatric Research, 41, 207A.
7. The Prevent Study Group. (1997). Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics, 99, 93-99.
8. Product Information. (1996). RespiGam. MedImmune, Inc., Gaithersburg, MD.
9. Robbins, J.M., Tilford, J.M., Jacobs, R.F., Wheeler, J.G., Gillaspy, S.R., & Schutze, G.E. (1997). A number needed to treat analysis of RSV-IG for the prevention of hospitalization [abstract]. Pediatric Research, 41, 97A.
10. Rodriguez, W.J., Gruber, W.C., Welliver, R.C., Groothuis, J.R., Simoes, E.A.F., Meissner, H.C., Hemming, V.G., Hall, C.B., Lepow, M.L., Rosas, A.J., Robertsen, C., & Kramer, A.A., for the RSVIG Study Group. (1997). Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatrics, 99, 454-461.
11. Sandritter, T.L., & Kraus, D.M. (1997). Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: Part I. Journal of Pediatric Health Care, 11, 284-293.
12. Simoes, E.A.F, Groothuis, J.R., Tristram, D.A., Allessi, K., Lehr, M.V., Siber, G.R., & Welliver, R.C. (1996a). Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. The Journal of Pediatrics, 129, 214-219.
13. Simoes, E.A.F., Sondheimer, H.M., Meissner, H.C., Welliver, R.C., Groothuis, J.R., & the RSVIG Cardiac Study Group. (1996b). Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease [abstract]. Pediatric Research, 39, 113A.
14. Smith, D.W., Frankel, L.R., Mathers, L.H., Tang, A.T.S., Ariagno, R.L., & Prober, C.G. (1991). A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. The New England Journal of Medicine, 325, 24-29.
15. Stevens, T.P., Hall, C.B., Maniscalco, W.M., & Sinkin, R.A. (1997). Risk of RSV-associated hospitalization and economic impact of RSV prophylaxis for premature infants bom <32 weeks gestation [abstract]. Pediatric Research, 41, 227A.
16. Taketomo, C.K., Hodding, J.H., & Kraus, D.M. (1997). Pediatric dosage handbook (4th ed., pp. 648-649). Cleveland, OH: Lexi-Comp Inc.
17. Wandstrat, T.L. (1997). Pharmacoeconomics of respiratory syncytial virus immune globulin intravenous [abstract]. Pediatric Research, 41, 133A.
18. Wojrynek, J.E. (1996). Respiratory syncytial virus-immune globulin (RespiGam). The Journal of Pediatric Pharmacy Practice, 1, 14-22.